An overview of currently available anti-insulin-like growth factor I receptor antibodies.
A number of studies during the last two decades revealed that the insulin-like growth factor I receptor (IGFIR) is an attractive target for cancer molecular therapy. Different molecular strategies have been developed and evaluated in experimental systems, and one such strategy involves anti-IGFIR antibodies, which have been rigorously tested for their therapeutic potential over the last 5-6 years. This mini-review thus introduces currently available IGFIR antibodies with a particular emphasis on epitope mapping and anti-IGFIR antibody-induced cancer growth inhibition.
Kusada
Yu
Y
Department of Applied Biochemistry, Tokai University School of Engineering, Hiratsuka, Kanagawa, Japan.
Fujita-Yamaguchi
Yoko
Y
D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D018604:Epitope Mapping / Q000379:methods; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000628:therapy*; D017526:Receptor, IGF Type 1 / Q000276:immunology*
D000906:Antibodies; D017526:Receptor, IGF Type 1